Kiniksa Pharmaceuticals International (KNSA) to Release Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, July 22nd. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.08 per share for the quarter. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. Kiniksa Pharmaceuticals International's revenue for the quarter was up 72.5% on a year-over-year basis. During the same period last year, the company posted ($0.25) EPS. On average, analysts expect Kiniksa Pharmaceuticals International to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Trading Up 1.0%

Shares of NASDAQ:KNSA traded up $0.29 during mid-day trading on Friday, reaching $29.13. The stock had a trading volume of 238,504 shares, compared to its average volume of 688,875. The firm has a market cap of $2.13 billion, a PE ratio of -116.58 and a beta of 0.05. The firm has a 50 day simple moving average of $27.84 and a two-hundred day simple moving average of $23.39. Kiniksa Pharmaceuticals International has a twelve month low of $17.82 and a twelve month high of $30.69.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 21,254 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $26.95, for a total transaction of $572,795.30. Following the completion of the transaction, the chief financial officer directly owned 27,009 shares of the company's stock, valued at $727,892.55. This trade represents a 44.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ross Moat sold 64,035 shares of the firm's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $25.21, for a total transaction of $1,614,322.35. Following the transaction, the insider directly owned 9,415 shares of the company's stock, valued at $237,352.15. This represents a 87.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 447,763 shares of company stock valued at $12,398,077 over the last quarter. Insiders own 53.48% of the company's stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. Amundi bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock valued at $507,000 after buying an additional 1,002 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after buying an additional 67,452 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KNSA has been the topic of several research analyst reports. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Wedbush restated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $39.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.